Zotarolimus-Eluting Stent for the Treatment of Recurrent, Severe Carotid Artery In-Stent Stenosis in the TARGET-CAS Population

Tekieli, Łukasz; Pienia̦żek, Piotr; Musiałek, Piotr; Kabłak‐Ziembicka, Anna; Przewłocki, Tadeusz; Trystuła, Mariusz; Moczulski, Zbigniew; Dzierwa, Karolina; Paluszek, Piotr; Podolec, Piotr

doi:10.1583/11-3805r.1

Cited by 31 publications

(41 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…CAS because of in-stent restenosis (18 cases-1.7%) was limited to the CAS <75 group. In-stent restenosis was treated either by balloon angioplasty or drug eluting stent implantation (DES), which were implanted in six patients (0.6%) because of recurrent carotid in-stent restenosis [21].…”

Section: Cas Proceduresmentioning

confidence: 99%

Carotid artery stenting according to the “tailored CAS” algorithm performed in the very elderly patients: The thirty day outcome

Dzierwa

Pienia̦żek

Tekieli

et al. 2013

Cathet Cardio Intervent

Self Cite

View full text Add to dashboard Cite

show abstract

Section: Cas Proceduresmentioning

confidence: 99%

Carotid artery stenting according to the “tailored CAS” algorithm performed in the very elderly patients: The thirty day outcome

Dzierwa

Pienia̦żek

Tekieli

et al. 2013

Cathet Cardio Intervent

Self Cite

View full text Add to dashboard Cite

show abstract

“…All endovascular procedures are affected by recurrent stenosis, and this main drawback of PTA of RAS has an average reported incidence rate of between 6.5% and 40% [18]. However, univocally different risk factors for RS in extra-coronary territory are postulated [28][29][30].…”

Section: Discussionmentioning

confidence: 99%

Long-term outcomes and determinants of stenosis recurrence after renal artery angioplasty in hypertensive patients with renovascular disease

Rosławiecka¹,

Kabłak‐Ziembicka²,

Badacz³

et al. 2020

pwki

View full text Add to dashboard Cite

Introduction: Restenosis (RS) following percutaneous angioplasty (PTA) of renal artery stenosis (RAS) might have an unfavourable impact on renal function and blood pressure (BP) outcomes. Aim: To evaluate the prevalence and predictors of RS in patients treated with PTA for RAS, and the relationship between BP and renal function (RF) changes with RS. Material and methods: We analysed freedom from RS in 210 patients (age 64.6 ±12.8 years; range: 20-85), who underwent 248 successful stent-assisted PTAs in RAS. The change in levels of serum creatinine (SCC), estimated glomerular filtration rate (eGFR), systolic/diastolic BPs (SBP/DBP) were analysed prior to PTA, at 6-, 12-month, and final follow-up visits, and whenever RS was diagnosed. Results: RS was identified in 30 (14.3%) patients, and there were 36 (14.5%) lesions. The Kaplan-Meier RS-free survival curves in fibromuscular dysplasia, atherosclerosis, and vasculitis at 1 and 7 years were: 100% and 100%; 95.6 and 83.9%; and 71.4 and 39.7%, respectively. Patients with RS, as compared to RS-free patients, presented with less pronounced changes in respect with:

show abstract

“…The third-generation DES show a strong focus on design and material, which makes them more flexible and highly deliverable. Some studies have experienced clinical success with DES in the carotid artery [36,37]; the results showed that this generation of DES can effectively diminish restenosis rates. …”

Section: Drug-eluting Stentsmentioning

confidence: 99%

The Development of Carotid Stent Material

Liu

Zhang

2014

Intervent Neurol

View full text Add to dashboard Cite

Endovascular angioplasty with stenting is a promising option for treating carotid artery stenosis. There exist a rapidly increasing number of different stent types with different materials. The bare-metal stent is the most commonly used stent with acceptable results, but it leaves us with the problems of thrombosis and restenosis. The drug-eluting stent is a breakthrough as it has the ability to reduce the restenosis rate, but the problem of late thrombosis still has to be addressed. The biodegradable stent disappears after having served its function. However, restenosis and degradation rates remain to be studied. In this article, we review every stent material with its characteristics, clinical results and complications and point out the standards of an ideal carotid stent. © 2014 S. Karger AG, Basel

show abstract

Zotarolimus-Eluting Stent for the Treatment of Recurrent, Severe Carotid Artery In-Stent Stenosis in the TARGET-CAS Population

Abstract: The use of coronary ZES in the treatment of recurrent carotid ISS is feasible and appears effective provided the ZES is placed entirely within the original stent. Placement of a coronary ZES outside the carotid stent scaffold should be avoided.

Cited by 31 publications

References 28 publications

Carotid artery stenting according to the “tailored CAS” algorithm performed in the very elderly patients: The thirty day outcome

Carotid artery stenting according to the “tailored CAS” algorithm performed in the very elderly patients: The thirty day outcome

Long-term outcomes and determinants of stenosis recurrence after renal artery angioplasty in hypertensive patients with renovascular disease

The Development of Carotid Stent Material

Contact Info

Product

Resources

About